Published in Cancer Res on January 11, 2012
Genetic Predictors of Benefit to Pembrolizumab | NCT02710396
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | NCT02963090
Cancer genome landscapes. Science (2013) 25.33
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
A survey of tools for variant analysis of next-generation genome sequencing data. Brief Bioinform (2013) 3.60
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature (2014) 3.42
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (2016) 3.38
PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol (2014) 3.02
Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature (2015) 2.76
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res (2014) 2.03
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood (2014) 1.92
The cancer antigenome. EMBO J (2012) 1.78
Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med (2014) 1.56
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res (2014) 1.56
Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett (2014) 1.55
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology (2012) 1.43
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res (2014) 1.37
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol (2015) 1.35
HLA typing from RNA-Seq sequence reads. Genome Med (2012) 1.34
Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res (2013) 1.32
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology (2014) 1.28
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer (2016) 1.22
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics (2014) 1.22
Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges. Cancer Immunol Immunother (2013) 1.19
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Oncolytic viruses as anticancer vaccines. Front Oncol (2014) 1.13
Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest (2015) 1.13
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J Pathol (2013) 1.09
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron (2012) 1.05
Elements of cancer immunity and the cancer-immune set point. Nature (2017) 1.05
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther (2012) 1.03
Can the exome and the immunome converge on the design of efficient cancer vaccines? Oncoimmunology (2012) 1.03
Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol (2013) 1.02
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. Oncoimmunology (2014) 1.00
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. Mol Ther (2015) 0.97
Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. J Immunother Cancer (2013) 0.96
Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol (2015) 0.96
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discov (2016) 0.96
The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol (2013) 0.94
pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med (2016) 0.94
HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines (2013) 0.94
Immunotherapy at large: the road to personalized cancer vaccines. Nat Med (2013) 0.93
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol (2014) 0.92
Cancer immunotherapy targeting neoantigens. Semin Immunol (2015) 0.92
In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census. Oncoimmunology (2012) 0.92
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91
Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother (2012) 0.90
Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology (2012) 0.90
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. Oncoimmunology (2014) 0.90
Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89
Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol (2013) 0.89
The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. J Immunother Cancer (2015) 0.88
Engineering T cells for cancer: our synthetic future. Immunol Rev (2014) 0.88
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside. Br J Cancer (2014) 0.87
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation. PLoS One (2013) 0.87
Whole Tumor Antigen Vaccines: Where Are We? Vaccines (Basel) (2015) 0.87
Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother (2016) 0.86
Mutated tumor alleles are expressed according to their DNA frequency. Sci Rep (2014) 0.85
Modeling Melanoma In Vitro and In Vivo. Healthcare (Basel) (2013) 0.85
Targeting neoantigens for cancer immunotherapy. Int Immunol (2016) 0.84
Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res (2015) 0.83
Identification of tumorigenic and therapeutically actionable mutations in transplantable mouse tumor cells by exome sequencing. Oncogenesis (2013) 0.83
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
Improving the clinical impact of biomaterials in cancer immunotherapy. Oncotarget (2016) 0.83
Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment. Nat Med (2016) 0.82
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Ann Oncol (2015) 0.82
Engineering opportunities in cancer immunotherapy. Proc Natl Acad Sci U S A (2015) 0.82
Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. Cancer Res (2016) 0.81
Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small (2015) 0.80
Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities. Front Immunol (2012) 0.80
Immunotherapy for Gastroesophageal Cancer. J Clin Med (2016) 0.80
T cell engineering as therapy for cancer and HIV: our synthetic future. Philos Trans R Soc Lond B Biol Sci (2015) 0.80
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS One (2016) 0.79
2015 Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Sci (2015) 0.79
A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines (2014) 0.79
Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma. Oncotarget (2015) 0.79
Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors. J Immunol (2015) 0.79
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines (2017) 0.79
A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer. PLoS One (2016) 0.78
Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci Immunol (2017) 0.78
Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. Oncoimmunology (2015) 0.78
Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano (2015) 0.78
Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw (2013) 0.77
NLRC5, a promising new entry in tumor immunology. J Immunother Cancer (2016) 0.77
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. Vaccines (Basel) (2015) 0.77
Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies. Oncoimmunology (2015) 0.77
Cancer immunotherapy: moving forward with peptide T cell vaccines. Curr Opin Immunol (2017) 0.76
New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies. Clin Cancer Res (2015) 0.76
Current tools for predicting cancer-specific T cell immunity. Oncoimmunology (2016) 0.76
Genomic landscape of DNA repair genes in cancer. Oncotarget (2016) 0.76
Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. Cancer Immunol Res (2016) 0.76
Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage (2005) 3.48
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood (2007) 2.61
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood (2005) 2.44
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) (2006) 2.23
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 2.22
Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (2010) 2.20
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood (2006) 2.00
The P4-type ATPase ATP11C is essential for B lymphopoiesis in adult bone marrow. Nat Immunol (2011) 1.96
Ongoing U snRNP biogenesis is required for the integrity of Cajal bodies. Mol Biol Cell (2006) 1.95
Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality. J Am Coll Cardiol (2011) 1.86
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res (2012) 1.83
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81
RNA-Seq Atlas--a reference database for gene expression profiling in normal tissue by next-generation sequencing. Bioinformatics (2012) 1.74
Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. Eur Heart J (2013) 1.70
An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice. Nat Genet (2004) 1.68
Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. J Exp Med (2008) 1.65
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood (2009) 1.58
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood (2004) 1.55
Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E-cadherin to disrupt intercellular adhesion. EMBO Rep (2010) 1.54
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood (2008) 1.51
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl) (2007) 1.49
Galaxy LIMS for next-generation sequencing. Bioinformatics (2013) 1.45
Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol (2012) 1.44
Digital genome-wide ncRNA expression, including SnoRNAs, across 11 human tissues using polyA-neutral amplification. PLoS One (2010) 1.42
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol (2006) 1.41
A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol (2011) 1.38
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res (2010) 1.38
Meeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshop. Stand Genomic Sci (2010) 1.35
Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol (2013) 1.35
Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J (2012) 1.33
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood (2004) 1.33
Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer (2007) 1.28
Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res (2005) 1.27
Confidence-based somatic mutation evaluation and prioritization. PLoS Comput Biol (2012) 1.25
Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett (2005) 1.25
A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res (2007) 1.24
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics (2014) 1.22
Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. EuroIntervention (2011) 1.22
Percutaneous management of vascular complications in patients undergoing transcatheter aortic valve implantation. JACC Cardiovasc Interv (2012) 1.19
The impact of harmonization on ELISPOT assay performance. Methods Mol Biol (2012) 1.18
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood (2006) 1.18
MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes. Cancer Res (2008) 1.16
Novel class of glycosphingolipids involved in male fertility. J Biol Chem (2005) 1.16
Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes. EuroIntervention (2012) 1.15
Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol (2011) 1.15
Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis. FASEB J (2003) 1.15
Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene (2011) 1.14
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res (2003) 1.12
Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol (2008) 1.12
Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes. Am Heart J (2011) 1.12
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A (2013) 1.11
Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res (2008) 1.08
Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Res (2002) 1.08